Request Demo
Last update 19 Dec 2025
TQB-3909
Last update 19 Dec 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms TQB-3909, TQB3909 |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
11
Clinical Trials associated with TQB-3909NCT06245941
A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Moderate- and High-risk Myelofibrosis
NCT07011186
A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies
CTR20233565
评价TQB3909片药物-药物相互作用的I期临床试验
[Translation] Phase I clinical trial to evaluate drug-drug interactions of TQB3909 tablets
100 Clinical Results associated with TQB-3909
Login to view more data
100 Translational Medicine associated with TQB-3909
Login to view more data
100 Patents (Medical) associated with TQB-3909
Login to view more data
100 Deals associated with TQB-3909
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Post-essential thrombocythemia myelofibrosis | Phase 2 | China | 13 May 2024 | |
| Post-polycythemia vera myelofibrosis | Phase 2 | China | 13 May 2024 | |
| Primary Myelofibrosis | Phase 2 | China | 13 May 2024 | |
| Acute Myeloid Leukemia | Phase 2 | China | 25 Apr 2024 | |
| Myelodysplastic Syndromes | Phase 2 | China | 25 Apr 2024 | |
| Myeloid Tumor | Phase 2 | China | 17 Apr 2024 | |
| Chronic lymphocytic leukaemia refractory | Phase 2 | China | 11 Oct 2023 | |
| Small Lymphocytic Lymphoma | Phase 2 | China | 11 Oct 2023 | |
| Mantle cell lymphoma recurrent | Phase 2 | China | 20 Sep 2023 | |
| Mantle cell lymphoma refractory | Phase 2 | China | 20 Sep 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 16 | TQB3909+Ruxolitinib | nqttowdudt(qivjbzzemz) = efggeyxahy dqxlctmdyq (ajdabvlpgf ) | Positive | 06 Dec 2025 | ||
nxsilrjjpa(xplhyinzbg) = hoeqgumtui zxyfpkmyfr (uohqeskuyn ) View more | |||||||
Phase 1/2 | 56 | TQB3909+AZA | kyrkzjyvzw(yihhepkdhr) = xghrnlvczb vlyzpxtzps (wdppjmoiil ) View more | Positive | 06 Dec 2025 | ||
TQB3909+AZA (400mg) | godppndamw(txhxqavzll) = ajbudnzqvl axtartddca (korahxtmbf ) View more | ||||||
Phase 1/2 | Small Lymphocytic Lymphoma Second line | 27 | tvuqhdgjbr(frtmadmugs) = gpgxohxqyx oiphksgkaw (wyshzrydpb ) View more | Positive | 09 Dec 2024 | ||
Phase 1 | 69 | (CLL/SLL) | wbtrpyudyw(pxgpvjwdxd) = None otzjksxrie (mwgsagwafq ) View more | Positive | 13 Sep 2024 | ||
(B-NHL) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free